Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intravesical Bacilli Calmette-Guerin (IVBCG) therapy for non-muscle invasive bladder cancer (NMIBC) has long been in use successfully. Albeit rarely, we still face with its safety concerns more than 25 years on since its approval by US Food and Drug Agency in 1990. Local and systemic infection following intravesical BCG is widely reported as compared to immune mediated local or systemic hypersensitivity reactions involving kidneys; acute kidney injury (AKI) and other renal manifestations are well reported but not of chronic kidney disease (CKD). CASE: following IVBCG for NMIBC. Our patient's renal function plateaued when IVBCG was held; and worsened again when reinstilled. It introduces the concept of 'repetitive' immune mediated renal injury presenting as progressive CKD rather than AKI, as is generally reported. Although response was poor, corticosteroids stopped CKD progression to end stage renal disease. CONCLUSIONS: We highlight the need for increased awareness and early recognition of IVBCG renal complications by both urologists and nephrologists in order to prevent progressive and irreversible renal damage. Low incidence of IVBCG renal complications may also be due to under recognition in the era prior to CKD Staging and AKI Network (and AKI e-alerts) that defined AKI as a rise in serum creatinine of ≥26umol/L; hence an unmet need for urgent prospective studies. Major literature review focuses on emerging spectrum of histopathological IVBCG related renal complications and their outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although corticosteroid therapy effectively mitigates the active inflammatory component, renal function recovery remains predominantly partial [5-8, 13-16].”
From Chronic Granulomatous Interstitial Nephritis Presenting Five Years After Intravesical Bacillus Calmette-Guérin Therapy: A Case Report and Literature Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This case is remarkable for its exceptionally long and unusual latency period, which generally manifests within days to months in other patients.”
From Chronic Granulomatous Interstitial Nephritis Presenting Five Years After Intravesical Bacillus Calmette-Guérin Therapy: A Case Report and Literature Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although corticosteroid therapy effectively mitigates the active inflammatory component, renal function recovery remains predominantly partial [5-8, 13-16].”
From Chronic Granulomatous Interstitial Nephritis Presenting Five Years After Intravesical Bacillus Calmette-Guérin Therapy: A Case Report and Literature Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classically, renal complications induced by intravesical BCG instillations--whether glomerular or tubulointerstitial--manifest acutely or subacutely.”
From Chronic Granulomatous Interstitial Nephritis Presenting Five Years After Intravesical Bacillus Calmette-Guérin Therapy: A Case Report and Literature Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978
Lamm, D. L., Van Der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A., & Debruyne, F. M. J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37316-0 · Cited by 786
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729 · cited 1×
“Antitumor effect and cytotoxicity is mediated via cytokine release and soluble factors such as TNF- α, IFN- γ and NO [7].”
BackgroundEfficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
Lamm, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/314064 · Cited by 264
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Spectrum of Bacille Calmette‐Guerin (BCG) Infection after Intravesical BCG Immunotherapy
Gonzalez, O. Y., Musher, D. M., Brar, I., Furgeson, S., Boktour, M. R., Septimus, E. J., Hamill, R. J., & Graviss, E. A. (2003) · Clinical Infectious Diseases · doi:10.1086/344908 · Cited by 195
Gender differences in incidence and outcomes of urothelial and kidney cancer
Lucca, I., Klatte, T., Fajković, H., de Martino, M., & Shariat, S. F. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.232 · Cited by 120
Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA
Gillespie, B. W., Morgenstern, H., Hedgeman, E., Tilea, A. M., Scholz, N., Shearon, T. H., Burrows, N. R., Shahinian, V. B., Yee, J., Plantinga, L., et al. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv103 · Cited by 101
Cited by
Vaccine-associated kidney diseases: A narrative review of the literature
Patel, C., & Shah, H. H. (2019) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.270254 · Cited by 46
Acute Kidney Injury in Cancer Immunotherapy Recipients
Joseph, A., Lafarge, A., Azoulay, É., & Zafrani, L. (2022) · Cells · doi:10.3390/cells11243991 · Cited by 25
Adverse Renal Effects of Anticancer Immunotherapy: A Review
Borówka, M., Łącki-Zynzeling, S., Nicze, M., Kozak, S., & Chudek, J. T. (2022) · Cancers · doi:10.3390/cancers14174086 · Cited by 22
Serum protein and electrolyte imbalances are associated with chemotherapy induced neutropenia
Abbasi, B., Hayat, A., Lyons, M., Gupta, A., & Gupta, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09949 · Cited by 20
The renal adverse effects of cancer immunotherapy
Steinel, N. C., Lee, E. M., Viggiano, D., Capasso, A., & Lee, M. W. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00691-2 · Cited by 12
Metadata
- Authors
- Mohammed, A., & Arastu, Z.
- Affiliations
- Royal Shrewsbury Hospital (GB)
- Corresponding author
- Mohammed, Azharuddin
- ORCID
- Mohammed, Azharuddin
- Venue
- BMC Urology
- Published
- 2017-12
- Volume
- 17
- Issue
- 1
- Pages
- 114-114
- ISSN
- 1471-2490 (ISSN-L)
- PMC
- PMC5719568
- OpenAlex
- W2772750305
- Cited by
- 20
- References
- 26
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 5 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Urology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- BCG immunotherapy, non-muscle-invasive bladder cancer, kidney injury, chronic kidney disease, acute kidney injury, hypersensitivity, corticosteroid therapy, end-stage renal disease, histopathology
- MeSH terms
- Administration, Intravesical, Aged, BCG Vaccine, Urinary Bladder Neoplasms, Female, Humans, Neoplasm Invasiveness, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer. https://app.cochat.ai/papers/10.1186/s12894-017-0304-5
- The paper
- Mohammed, A., & Arastu, Z. (2017). Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer. BMC Urology. https://doi.org/10.1186/s12894-017-0304-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

